Durvalumab,BA3011,BA3021
BioAtla,Astrazeneca
['ovarian']
dr helen mackay presenting our ongoing trial ind.240 #asco23 for patients with high grade serous ovarian cancer 
The Investigational New Drug Program of the Canadian Cancer Trials Group